Related Experiment Video
Updated: Sep 2, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
Neuromyelitis optica spectrum disorder overlapping with Sjögren's disease: immunopathological links and therapeutic
Wanfeng Xu1, Haoyue Xing1, Ling Hou2
1Department of Endocrinology, Shengjing Hospital of China Medical University, Shenyang, China.
Abstract:
Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease that mostly affects the central nervous system, and Sjögren's disease (SjD) is an autoimmune disease that mostly affects the exocrine glands. Recent evidence indicates that these conditions frequently coexist and may have overlapping immunopathogenic mechanisms. Patients with NMOSD often exhibit serological or clinical features of SjD, and patients with SjD may develop inflammatory demyelinating events resembling NMOSD. This overlap can pose significant diagnostic and therapeutic challenges. Our narrative review synthesizes recent evidence on the epidemiology, clinical characteristics, immunopathogenic links, diagnostic considerations, and therapeutic implications of NMOSD-SjD overlap. This overlap phenotype is characterized by a diverse autoantibody profile, B-cell hyperactivity, cytokine dysregulation (particularly interleukin-6 and type I interferon signaling), and loss of immune tolerance. Blood-brain barrier dysfunction may enable circulating pathogenic antibodies and inflammatory mediators to access the central nervous system, although direct evidence for this in the overlap disease remains limited. We propose a structured diagnostic approach that integrates clinical phenotype, antibody testing, neuroimaging, and systemic autoimmune assessment to distinguish NMOSD-SjD overlap from SjD-related central nervous system involvement and myelin oligodendrocyte glycoprotein antibody-associated disease. We also describe therapeutic strategies that emphasize prevention of NMOSD relapse, selection of biologic treatments, assessment of systemic safety, and avoidance of misclassification. Recognition of NMOSD-SjD overlap has important implications for personalized diagnosis, assessment of systemic risk, and long-term management, and illustrates the relationship of systemic autoimmunity with organ-specific antibody-mediated central nervous system disease.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Multiple Sclerosis l: Introduction
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Glaucoma: Overview
Autoimmune Disorders
Concept and Mechanism of Autoimmune Diseases
The immune system...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...